Histone modifications play a key role in the epigenetic regulation of gene transcription in cancer cells. Histone acetylations are regulated by two classes of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are increased in ovarian carcinomas and they are involved in carcinogenesis and resistance to chemotherapeutic agents. In our study we investigated anticancer effect of HDAC inhibitor sodium butyrate (NaBu) on cisplatin-sensitive and cisplatin-resistant ovarian cell lines A2780 and A2780cis. A2780 and A2780cis were treated with NaBu alone or in combination with cisplatin (CP). NaBu inhibited the growth of both cell lines and enhanced cytotoxic effect of CP. Exposure to NaBu for 24 h induced cell cycle arrest. The expressions of EMT-related genes and proteins were further investigated by qPCR and western blot analysis. Loss of E-cadherin has been shown to be crucial in ovarian cancer development. We found that NaBu dramatically induce expression of E-cadherin gene (CDH1) and protein levels in A2780 and A2780cis. We investigated correlation between transcription and methylation of CDH1gene. Methylation level analysis in 32 CpG sites in CDH1 gene (promoter/exon1 regions) was performed using bisulfite NGS (Next Generation Sequencing). We found that cisplatin-resistant cell line A2780cis cells differ from their cisplatin-sensitive counterparts in the CDH1 methylation. Methylation in A2780cis cells is elevated compared to A2780. However, NaBu-induced expression of CDH1 was not accompanied by CDH1 demethylation. NaBu treatment induced changes in expression of EMT-related genes and proteins. Interestingly E-cadherin zinc finger transcriptional repressor SNAIL1 was upregulated in both cell lines. Mesenchymal marker vimentin was downregulated. Matrix metalloproteases (MMPs) are necessary for pericellular proteolysis and facilitate migration and invasion of tumour cells. NaBu induced mRNA expression of MMPs, mild changes in activities of gelatinases MMP2 and MMP9 were detected. Our data demonstrate that NaBu sensitizes cisplatin-resistant ovarian cancer cells, re-established E-cadherin expression, but it was not able to reverse the EMT phenotype completely.

2nd Department of Internal Medicine Gastroenterology Faculty of Medicine in Hradec Kralove Charles University and University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Biology Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Department of Medical Biochemistry Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Institute for Clinical Biochemistry and Diagnostics Faculty of Medicine in Hradec Kralove Charles University and University Hospital Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32. 10.20892/j.issn.2095-3941.2016.0084 PubMed DOI PMC

Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol. 2002;22(9):3157–73. 10.1128/MCB.22.9.3157-3173.2002 PubMed DOI PMC

Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH, et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. Journal of gynecologic oncology. 2008;19(3):185–90. 10.3802/jgo.2008.19.3.185 PubMed DOI PMC

Eckstein N. Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Canc Res. 2011;30 10.1186/1756-9966-30-91 PubMed DOI PMC

Koberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: Preclinical findings and clinical implications. Bba-Rev Cancer. 2010;1806(2):172–82. 10.1016/j.bbcan.2010.07.004 PubMed DOI

Issa ME, Takhsha FS, Chirumamilla CS, Perez-Novo C, Berghe WV, Cuendet M. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics. 2017;9 10.1186/s13148-017-0319-5 PubMed DOI PMC

Montani MSG, Granato M, Santoni C, Del Porto P, Merendino N, D’Orazi G, et al. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cell Oncol. 2017;40(2):167–80. 10.1007/s13402-017-0314-z PubMed DOI

Lapinska K, Housman G, Byler S, Heerboth S, Willbanks A, Oza A, et al. The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells. Anticancer Res. 2016;36(11):5731–42. 10.21873/anticanres.11156 PubMed DOI

Koprinarova M, Markovska P, Iliev I, Anachkova B, Russev G. Sodium butyrate butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest. Bmc Mol Biol. 2010;11 10.1186/1471-2199-11-49 PubMed DOI PMC

Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Frontiers in oncology. 2012;2:33 10.3389/fonc.2012.00033 PubMed DOI PMC

Kang YB, Massague J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 2004;118(3):277–9. 10.1016/j.cell.2004.07.011 PubMed DOI

Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Bio. 2014;15(3):178–96. 10.1038/nrm3758 PubMed DOI PMC

Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol. 2004;24(1):306–19. 10.1128/MCB.24.1.306-319.2004 PubMed DOI PMC

Barton CA, Hacker NF, Clark SJ, O’Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecologic oncology. 2008;109(1):129–39. 10.1016/j.ygyno.2007.12.017 . PubMed DOI

Kwiecinska P, Wrobel A, Tauboll E, Gregoraszczuk EL. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells. Toxicol Lett. 2014;224(2):225–32. 10.1016/j.toxlet.2013.10.035 PubMed DOI

Kim MG, Pak JH, Choi WH, Park JY, Nam JH, Kim JH. The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. Journal of gynecologic oncology. 2012;23(3):182–9. 10.3802/jgo.2012.23.3.182 PubMed DOI PMC

Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer. 2004;101(12):2760–70. 10.1002/cncr.20709 PubMed DOI

Muenyi CS, Trivedi AP, Helm CW, States JC. Cisplatin Plus Sodium Arsenite and Hyperthermia Induces Pseudo-G1 Associated Apoptotic Cell Death in Ovarian Cancer Cells. Toxicol Sci. 2014;139(1):74–82. 10.1093/toxsci/kfu029 PubMed DOI PMC

Wilkins DE, Ng CE, Raaphorst GP. Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation. Cancer Chemoth Pharm. 1997;40(2):159–66. 10.1007/s002800050641 PubMed DOI

Pani E, Stojic L, El-Shemerly M, Jiricny J, Ferrari S. Mismatch repair status and the response of human cells to cisplatin. Cell Cycle. 2007;6(14):1796–802. 10.4161/cc.6.14.4472 PubMed DOI

Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. International journal of oncology. 2006;28(5):1233–41. PubMed

Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor perspectives in biology. 2009;1(6):a003129 10.1101/cshperspect.a003129 PubMed DOI PMC

Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol. 2015;9(8):1678–93. 10.1016/j.molonc.2015.04.015 PubMed DOI PMC

Tian XJ, Zhang H, Xing JH. Coupled Reversible and Irreversible Bistable Switches Underlying TGF beta-induced Epithelial to Mesenchymal Transition. Biophys J. 2013;105(4):1079–89. 10.1016/j.bpj.2013.07.011 PubMed DOI PMC

Javaid S, Zhang J, Anderssen E, Black JC, Wittner BS, Tajima K, et al. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 2013;5(6):1679–89. 10.1016/j.celrep.2013.11.034 PubMed DOI PMC

Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. Plos One. 2012;7(9):e45045 10.1371/journal.pone.0045045 PubMed DOI PMC

Feng J, Cen J, Li J, Zhao R, Zhu C, Wang Z, et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail. Cell Adh Migr. 2015;9(6):495–501. 10.1080/19336918.2015.1112486 PubMed DOI PMC

Giudice FS, Pinto DS, Nor JE, Squarize CH, Castilho RM. Inhibition of Histone Deacetylase Impacts Cancer Stem Cells and Induces Epithelial-Mesenchyme Transition of Head and Neck Cancer. Plos One. 2013;8(3). 10.1371/journal.pone.0058672 PubMed DOI PMC

Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, et al. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Bba-Mol Cell Res. 2013;1833(3):663–71. 10.1016/j.bbamcr.2012.12.002 PubMed DOI

Chen X, Xiao W, Chen W, Luo L, Ye S, Liu Y. The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells. Cell Death Dis. 2013;4 10.1038/cddis.2013.416 PubMed DOI PMC

Ganatra DA, Rajkumar S, Patel AR, Gajjar DU, Johar K, Arora AI, et al. Association of histone acetylation at the ACTA2 promoter region with epithelial mesenchymal transition of lens epithelial cells. Eye. 2015;29(6):828–38. 10.1038/eye.2015.29 PubMed DOI PMC

Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta 1 in human renal epithelial cells. J Am Soc Nephrol. 2007;18(1):58–65. 10.1681/ASN.2005111187 PubMed DOI

Lei WW, Zhang KH, Pan XC, Hu Y, Wang DM, Yuan XW, et al. Histone deacetylase 1 is required for transforming growth factor-beta 1-induced epithelial-mesenchymal transition. Int J Biochem Cell B. 2010;42(9):1489–97. 10.1016/j.biocel.2010.05.006 PubMed DOI

Noguchi S, Eitoku M, Moriya S, Kondo S, Kiyosawa H, Watanabe T, et al. Regulation of Gene Expression by Sodium Valproate in Epithelial-to-Mesenchymal Transition. Lung. 2015;193(5):691–700. 10.1007/s00408-015-9776-9 PubMed DOI

Chen CA, Chiang YC, Chang MC, Hu YH, You SL, Cheng YYK, et al. Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. Am J Transl Res. 2015;7(1):139–52. PubMed PMC

Boettcher M, Kischkel F, Hoheisel JD. High-Definition DNA Methylation Profiles from Breast and Ovarian Carcinoma Cell Lines with Differing Doxorubicin Resistance. Plos One. 2010;5(6). 10.1371/journal.pone.0011002 PubMed DOI PMC

Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV. Histone Deacetylase Inhibitors Reverse CpG Methylation by Regulating DNMT1 through ERK Signaling. Anticancer Res. 2011;31(9):2723–32. PubMed

Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CSM, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012;31(42):4567–76. 10.1038/onc.2011.611 PubMed DOI

Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2(2):84–9. 10.1038/35000034 PubMed DOI

Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 2010;29(24):3490–500. 10.1038/onc.2010.102 PubMed DOI

Jolly MK, Boareto M, Huang B, Jia DY, Lu MY, Ben-Jacob E, et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Frontiers in oncology. 2015;5 10.3389/Fonc.2015.00155 PubMed DOI PMC

Labrie M, St-Pierre Y. Epigenetic regulation of mmp-9 gene expression. Cell Mol Life Sci. 2013;70(17):3109–24. 10.1007/s00018-012-1214-z PubMed DOI PMC

Januchowski R, Zawierucha P, Rucinski M, Nowicki M, Zabel M. Extracellular Matrix Proteins Expression Profiling in Chemoresistant Variants of the A2780 Ovarian Cancer Cell Line. Biomed Res Int. 2014. 10.1155/2014/365867 PubMed DOI PMC

Nural-Guvener HF, Zakharova L, Nimlos J, Popovic S, Mastroeni D, Gaballa MA. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis & tissue repair. 2014;7:10 10.1186/1755-1536-7-10 PubMed DOI PMC

Lu HG, Zhan W, Yan L, Qin RY, Yan YP, Yang ZJ, et al. TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion. Mol Med Rep. 2014;10(5):2595–600. 10.3892/mmr.2014.2517 PubMed DOI